Results 31 to 40 of about 8,326 (241)

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. [PDF]

, 2016
Chemotherapy-induced nausea and vomiting (CINV) is presented in over 30% of cancer patients receiving highly/moderately emetogenic chemotherapy (HEC/MEC).
Chan, Alexandre, Chen, Likun, Hu, Zhihuang, Huang, Yan, Keefe, Dorothy, Liang, Wenhua, Ma, Yuxiang, Xue, Cong, Yang, Yunpeng, Zhang, Li, Zhao, Hongyun, Zhao, Yuanyuan   +11 more
core   +2 more sources

Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer. [PDF]

, 2011
Patients reported a negative impact on the QoL of delayed emesis after chemotherapy. Poor prophylaxis of patients' nausea and vomiting after chemotherapy interferes with patients' QoL.
Atthobari, Jarir, Dwiprahasto, Iwan, Gelderblom, Hans, Guchelaar, Henk-Jan, Hakimi, Mohammad, Kaptein, Ad A, Mustofa, Mustofa, Nortier, Johan W R, Perwitasari, Dyah Aryani, Putter, Hein   +9 more
core   +1 more source

The SP/NK1R System-Mediated ROS Generation in GBM Cells through Inhibiting Glutaredoxin Protein

Neurology Research International, 2021
Altered redox balance is among the main contributing factors developing glioblastoma multiforme (GBM), a highly aggressive grade IV brain tumor. Neuropeptide substance P (SP) plays a key role in modifying the cellular redox environment by activating the ...
Negeen Mehrabani, Mohammad Reza Vaezi Kakhki, Hossein Javid, Safieh Ebrahimi, Seyed Isaac Hashemy   +4 more
doaj   +1 more source

Effects of aprepitant on post-operative nausea and vomiting in patients with congenital heart disease undergoing cardiac surgery or catheterization procedures: a retrospective study with subjects as their own historical control

Frontiers in Anesthesiology, 2023
IntroductionFor patients undergoing cardiac surgery and catheterization procedures, severe post-operative nausea and vomiting (PONV) can occur despite standard anti-emetic interventions.
John W. Belk, Mark D. Twite, Katherine S. Klockau, Lori J. Silveira, Rachel G. Clopton   +4 more
doaj   +1 more source

Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs [PDF]

, 2018
Upon oral administration the solubility of a drug in intestinal fluid is a key property influencing bioavailability. It is also recognised that simple aqueous solubility does not reflect intestinal solubility and to optimise in vitro investigations ...
Dunn, Claire, Halbert, Gavin, Khadra, Ibrahim, Perrier, Jeremy, Wilson, Clive G., Zhou, Zhou   +5 more
core   +1 more source

Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients

Zhongliu Fangzhi Yanjiu, 2018
Objective To observe the curative effect of aprepitant on chemotherapy-induced nausea and vomiting(CINV) and hemoglobin level in gynecological malignancy patients.
HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi   +7 more
doaj   +1 more source

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies

Cancer Biology & Medicine, 2021
Objective: Chemotherapy-induced nausea and vomiting (CINV) are common with doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor ...
Winnie Yeo, Leung Li, Thomas KH Lau, Kwai T Lai, Vicky TC Chan, Kwan H Wong, Christopher CH Yip, Elizabeth Pang, Maggie Cheung, Vivian Chan, Carol CH Kwok, Joyce JS Suen, Frankie KF Mo   +12 more
doaj   +1 more source

Antiemetic research: future directions [PDF]

, 2010
PURPOSE AND METHODS: As a part of reviewing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines in Perugia in 2009, an expert group identified directions for future antiemetic research.
Aapro, Matti, Grunberg, Steven, Herrstedt, Jørn, Molassiotis, Alexander, Morrow, Garry, Olver, Ian   +5 more
core   +1 more source

Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography

Nature Communications, 2019
The FDA approved drug aprepitant is an antagonist of the Neurokinin 1 receptor (NK1R). Here the authors present aprepitant bound NK1R crystal structures and use NMR spectroscopy to gain further insights into the dynamics of aprepitant binding, which is ...
Shuanghong Chen, Mengjie Lu, Dongsheng Liu, Lingyun Yang, Cuiying Yi, Limin Ma, Hui Zhang, Qing Liu, Thomas M. Frimurer, Ming-Wei Wang, Thue W. Schwartz, Raymond C. Stevens, Beili Wu, Kurt Wüthrich, Qiang Zhao   +14 more
doaj   +1 more source

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Cancer Medicine, 2023
Introduction Non‐inferiority of NEPA (fixed combination of NK1 receptor antagonist (RA), netupitant, and 5‐HT3RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide ...
Laurent Zelek, Rudolph Navari, Matti Aapro, Florian Scotté   +3 more
doaj   +1 more source